MOC News and Press, Command Security Corporation

OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases. Obtaining regulatory approvals in Denmark, France, Greece, Germany, and Norway enables the conduct of the Phase II clinic...

Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...

- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces part of the results of the work program consisting of eight drill holes for a total of 2,484 meters on the Gaboury project . Highlig...

MONTRÉAL, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“ Mosaic ” or the “ Corporation ”) is pleased to announce that it has closed an oversubscribed private placement (the “ Offering ”), pursuant to which...

MONTREAL, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces that it has completed eight drill holes for a total of 2,475 meters on its Gaboury nickel project located in Témiscamingue, Quebec. ...

MONTREAL, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) is pleased to announce the start of a drilling program of a minimum of 2,000 meters on the Gaboury project located in Témiscamingue, Quebec. The ...

U.S. Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial for novel chitinase inhibitor OATD-01 in pulmonary sarcoidosis with first patient expected to be dosed in fourth quarter of 2023 Continued enrollment in the Phase I clinical trial of OATD-02, an oral, fi...

MONTREAL, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces the start of a ten-day prospecting program on the Amanda project . The team, composed of a geologist and two technicians, will revisit, and ...

Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseases Completed successful Secondary Public Offering (SPO) of gross proceeds of approximately PLN50 ...